Market closed
Ardelyx/$ARDX
Ardelyx shares are trading lower after the company reported Q1 results with revenue below expectations and increased losses, amid reimbursement challenges for XPHOZAH.
7 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ardelyx
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ticker
$ARDX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
395
Website
Ardelyx Metrics
BasicAdvanced
$1.3B
-
-$0.17
0.85
-
Price and volume
Market cap
$1.3B
Beta
0.85
52-week high
$9.33
52-week low
$4.02
Average daily volume
5.4M
Financial strength
Current ratio
4.58
Quick ratio
3.955
Long term debt to equity
102.374
Total debt to equity
103.275
Interest coverage (TTM)
-1.39%
Management effectiveness
Return on assets (TTM)
-4.76%
Return on equity (TTM)
-23.01%
Valuation
Price to revenue (TTM)
3.857
Price to book
7.51
Price to tangible book (TTM)
7.51
Price to free cash flow (TTM)
-28.082
Growth
Revenue change (TTM)
168.06%
Earnings per share change (TTM)
-44.77%
3-year revenue growth (CAGR)
220.89%
3-year earnings per share growth (CAGR)
-52.17%
What the Analysts think about Ardelyx
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.
Ardelyx Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Ardelyx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Ardelyx News
AllArticlesVideos
Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty
Seeking Alpha·14 hours ago
Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript
Seeking Alpha·1 day ago
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ardelyx stock?
Ardelyx (ARDX) has a market cap of $1.3B as of May 03, 2025.
What is the P/E ratio for Ardelyx stock?
The price to earnings (P/E) ratio for Ardelyx (ARDX) stock is 0 as of May 03, 2025.
Does Ardelyx stock pay dividends?
No, Ardelyx (ARDX) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Ardelyx dividend payment date?
Ardelyx (ARDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Ardelyx?
Ardelyx (ARDX) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.